A synthetic peptide for use as a blocking control in assays to test for specificity of SCARB2 antibody, Alternative Names: SCARB2 control peptide, SCARB2 antibody Blocking Peptide, Anti-SCARB2 Blocking Peptide, scavenger receptor class B, member 2 Blocking Peptide, AMRF Blocking Peptide, CD36L2 Blocking Peptide, HLGP85 Blocking Peptide, LIMPII Blocking Peptide, SR-BII Blocking Peptide, SCARB2, SCARB-2, SCARB 2, SCARB-2 Blocking Peptide, SCARB 2 Blocking Peptide
Optimal conditions should be determined by the investigator
Beschränkungen
Nur für Forschungszwecke einsetzbar
Format
Lyophilized
Rekonstitution
Add 100 µL of distilled water for a final peptide concentration is 1 mg/mL.
Buffer
PBS
Handhabung
Avoid repeated freeze/thaw cycles.
Lagerung
-20 °C
Informationen zur Lagerung
Store at -20 °C long term.
Target
SCARB2
(Scavenger Receptor Class B, Member 2 (SCARB2))
Hintergrund
The protein encoded by this gene is a type III glycoprotein that is located primarily in limiting membranes of lysosomes and endosomes. Earlier studies in mice and rat suggested that this protein may participate in membrane transportation and the reorganization of endosomal/lysosomal compartment. The protein deficiency in mice was reported to impair cell membrane transport processes and cause pelvic junction obstruction, deafness, and peripheral neuropathy. Further studies in human showed that this protein is a ubiquitously expressed protein and that it is involved in the pathogenesis of HFMD (hand, foot, and mouth disease) caused by enterovirus-71 and possibly by coxsackievirus A16. Mutations in this gene caused an autosomal recessive progressive myoclonic epilepsy-4 (EPM4), also known as action myoclonus-renal failure syndrome (AMRF).